Prothena (PRTA) Expected to Announce Earnings on Thursday

Prothena (NASDAQ:PRTA) is projected to post its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Prothena to post earnings of ($0.31) per share and revenue of $0.8090 million for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:00 PM ET.

Prothena (NASDAQ:PRTA) last posted its earnings results on Thursday, February 19th. The biotechnology company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.01. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.67 million. Prothena had a negative return on equity of 65.89% and a negative net margin of 2,520.57%. On average, analysts expect Prothena to post $1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Prothena Stock Performance

Shares of NASDAQ:PRTA traded up $0.39 during midday trading on Tuesday, hitting $11.18. 205,830 shares of the stock were exchanged, compared to its average volume of 488,674. The stock has a market capitalization of $601.71 million, a price-to-earnings ratio of -2.46, a P/E/G ratio of 0.37 and a beta of -0.23. The business’s 50-day moving average price is $9.80 and its 200 day moving average price is $9.79. Prothena has a 12 month low of $4.32 and a 12 month high of $11.69.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Intech Investment Management LLC lifted its position in shares of Prothena by 5.5% in the 3rd quarter. Intech Investment Management LLC now owns 19,388 shares of the biotechnology company’s stock worth $189,000 after purchasing an additional 1,014 shares during the period. Brooklyn Investment Group raised its stake in Prothena by 13.1% during the third quarter. Brooklyn Investment Group now owns 12,569 shares of the biotechnology company’s stock worth $123,000 after buying an additional 1,456 shares during the last quarter. Deutsche Bank AG raised its stake in Prothena by 5.1% during the fourth quarter. Deutsche Bank AG now owns 35,482 shares of the biotechnology company’s stock worth $339,000 after buying an additional 1,709 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Prothena by 3.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 81,515 shares of the biotechnology company’s stock valued at $779,000 after buying an additional 2,968 shares during the period. Finally, Virtus Investment Advisers LLC lifted its holdings in Prothena by 14.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 25,679 shares of the biotechnology company’s stock valued at $245,000 after buying an additional 3,236 shares during the period. Institutional investors own 97.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Stifel Nicolaus set a $19.00 target price on shares of Prothena in a research report on Friday, March 13th. Citigroup reaffirmed a “market outperform” rating on shares of Prothena in a research note on Friday, March 13th. Weiss Ratings lowered shares of Prothena from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, April 27th. Finally, Royal Bank Of Canada boosted their price objective on shares of Prothena from $11.00 to $12.00 and gave the stock a “sector perform” rating in a research note on Friday, February 20th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $21.67.

Prothena Company Profile

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.